IRCT201702171556N96招募中未知
Palmitoylethanolamide as adjunctive treatment of Autism: A double blind and placebo controlled trial
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 4 years 至 12 years（—）
- 性别
- All
入选标准
- •Inclusion Criteria: 1-DSM 5 clinical diagnosis of autistic disorder; 2-children between the ages of 4 and 11 years old; 3- presence of behavioral problems such as aggression, overactivity or repetitive behaviors (indication of treatment with risperidone).
排除标准
- •1- Presence of any active medical problem; 2-any other psychiatric diagnosis except for Intellectual disability; 3-history of allergy or intolerance to Risperidone; 4- receiving any psychotropic medications during past two weeks prior to the trial; 5-presence of hepatic disease resulting impairment of liver function or rising hepatic enzymes; 6-history of seizure during the last 6 months.
研究者
相似试验
尚未招募
4 期
Palmitoylethanolamide for the treatment of centralised chronic paiChronic PainAnaesthesiology - Pain managementACTRN12619000418178Daniel Ellyard100
尚未招募
2 期
The effect of Palmitoylethanolamide on the treatment of negative symptoms in patients with chronic schizophreniaSchizophreniaIRCT20090117001556N127Tehran University of Medical Sciences50
招募中
不适用
Palmitoylethanolamide in the treatment of major depressioMajor Depressive Disorder.Major Depressive DisorderIRCT201702181556N97Tehran University of Medical Sciences50
已完成
3 期
The effect of Palmitoylethanolamide (PEA) supplementation on the symptoms of allergic rhinitis - A double-blind placebo controlled trial.Allergic rhinitisInflammatory and Immune System - AllergiesACTRN12619001368123RDC Global Pty Ltd162
已完成
不适用
Can muscle growth and strength gains from weight training in young, active, healthy adults be affected by supplementing with palmitoylethanolamide?Skeletal muscleMusculoskeletal - Normal musculoskeletal and cartilage development and functionACTRN12621001726842Deakin University50